# Pazopanib in Molecularly Selected Patients With Advanced NSCLC

> **NCT02193152** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 16 (actual)

## Conditions studied

- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT02193152
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-27
- **Primary completion:** 2019-12-24
- **Final completion:** 2019-12-24
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Terminated by sponsor
- **Last updated:** 2020-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02193152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02193152, "Pazopanib in Molecularly Selected Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02193152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*